"Bear, like Biogen's claim for aducanumab, would higher doses of ABL in the BOM trial produced a better outcome?"

There is no information available to me to answer this question with much certainty either way. The only trial I know of that doses higher is Phase 2 ASSERT, but that trial dosed for only 12 weeks. That study is published and some other ASSERT post-hoc follow ups have been done on those patient samples. There were some biomarkers that responded more robustly with higher dosing of 300 mg/day instead of 200 mg/day, but also liver enzyme elevations were more pronounced at higher dosing. Always a balance between finding the balance between efficacy and safety.

BDAZ